Document › Details
Phenomenome Discoveries Inc.. (6/28/12). "Press Release: Phenomenome Discoveries and Polymedco Cancer Diagnostic Products Jointly Announce US Commercial Licensing Agreement". Saskatoon & Cortlandt Manor, NY.
|Region||United States (USA)|
|Organisation||Phenomenome Discoveries Inc. (PDI)|
|Organisation 2||Polymedco Cancer Diagnostic Products LLC|
|Product||triple quadrupole mass spectrometer|
|Person||Hyshka, John (Phenomenome Discoveries 201206 CFO + COO)|
|Person 2||Goodenowe, Dayan (Phenomenome Discoveries 201206 CEO)|
Phenomenome Discoveries Inc. ("PDI") and Polymedco Cancer Diagnostic Products LLC. ("Polymedco CDP") are pleased to announce a commercial licensing agreement for the US market, providing rights to Polymedco to commercialize PDI's diagnostic blood test that assesses an individual's risk of colorectal cancer ("CRC").
Using patented technology, PDI has discovered that approximately nine out of ten patients with CRC are deficient in novel anti-cancer and anti-inflammatory metabolites in their blood. PDI has developed a convenient blood test assayed by triple quad mass spectrometry that can detect this deficiency. PDI's blood test is a simple non-invasive means of identifying individuals with increased risk of CRC. This blood test is expected to significantly improve CRC screening compliance.
On May 18, 2012 PDI presented results from a landmark multi-site, six thousand subject clinical trial evaluating the performance of the CRC test at the Digestive Disease Week (DDW) meeting in San Diego in which the blood test was found to detect over 85% of early stage CRC. DDW is the largest and most prestigious meeting in the world for GI professionals. Every year it attracts approximately 16,000 physicians, researchers and academics from around the world.
"We are extremely pleased to be working with Polymedco to commercialize this test in the US market," said John Hyshka, PDI's Chief Financial and Operating Officer, "PDI has a number of similar products that are nearing market launch, and Polymedco's unparalleled expertise as a world-leader in marketing and distributing non-invasive colorectal cancer screening products is very valuable."
Dr. Dayan Goodenowe, PDI's President and CEO, says "Polymedco's proficiency has enabled us to exceed our goals and timelines around making this test available in the US. A month ago, we jointly submitted an application for FDA premarket review, and we look forward to receiving approval and moving ahead with our shared commercialization strategy."
"We are excited about this new alliance with Phenomenome Discoveries. This new non-invasive technology adds to our cancer testing portfolio of market leading tests. We believe that this test will facilitate the screening of more patients annually for colorectal cancer. Increased screening rates will detect more cancers at an earlier stage, resulting in more lives saved," said Drew Cervasio, President of Polymedco Cancer Diagnostic Products.
About Phenomenome Discoveries Inc.
Phenomenome Discoveries Inc. (PDI) is a Saskatoon, Canada based human health research company, focusing on the discovery and development of novel disease screening, treatment and health monitoring products. Founded in 2000 and privately owned, PDI uses its patented biomarker discovery platform to discover and develop new biomarkers for cancer and neurodegenerative disorders and has launched therapeutics and diagnostics divisions based on the results of its research. For more information please visit http://www.phenomenome.com/.
About Polymedco Cancer Diagnostic Products, LLC
Polymedco Cancer Diagnostic Products, LLC is a leading manufacturer, marketer, and distributer in the clinical laboratory marketplace. Polymedco supplies clinical diagnostic test kits and devices that are specialized in cancer. We are a world leader in non-invasive colorectal cancer screening technology, providing the new standard of care with the OC -Auto® product line. Since 1980, Polymedco has evolved into a highly skilled and successful marketing, sales, and manufacturing organization.
Combined with an experienced team of field representatives and strong technical service personnel, Polymedco Cancer Diagnostic Products provides a high level of customer, technical and reimbursement support. To reach Polymedco Inc. via the worldwide web, log on to http://www.polymedco.com/.
For more information, please contact:
Director of Operations Vice President of Operations
Phenomenome Discoveries Inc.
(306) 244-8233, ext 210
Rick De Alto
Vice President of Operations
Polymedco Cancer Diagnostic Products, LLC
(914) 739-5400, ext 216
Record changed: 2016-03-19
More documents for Phenomenome Discoveries Inc. (PDI)
-  Ionics Mass Spectrometry Group Inc.. (5/31/09). "Press Release: Ionics Announces the Product Release of the IONICS 3Q Molecular Analyzer and MolAna Acquisition and Quantitation Software". Philadelphia, PA....
-  Phenomenome Discoveries Inc.. (5/24/06). "Press Release: Shimadzu Corporation and Phenomenome Discoveries Announce an Exclusive Collaboration in Developing Software Tools for Global Profiling Using High Mass Accuracy MSn Data ". Koyoto, Japan....
-  Phenomenome Discoveries Inc.. (10/18/05). "Press Release: Shimadzu Corporation and Phenomenome Discoveries Inc. Form Worldwide Distribution Agreement on Phenomenome Profiler™ Metabolomics Software". Saskatoon & Kyoto....
-  Phenomenome Discoveries Inc.. (6/2/05). "Press Release: Shimadzu Corporation and Phenomenome Discoveries Announce a Collaboration in the Development of Software Tools and Instrumentation for Metabolomics". Saskatoon....
-  MDS Sciex. (3/1/05). "Press Release: Applied Biosystems/MDS Sciex and Phenomenome Discoveries Announces Metabolomics Agreement". Foster City, CA....
To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to email@example.com and simply fill the subject line with the word »MSC newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]